Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
What's Your Reaction?
